Aclarion Announces 1-for-335 Reverse Stock Split to Maintain Nasdaq Listing

Healthcare technology company Aclarion (Nasdaq: ACON) has announced a 1-for-335 reverse stock split of its common stock, effective January 30, 2025, in an effort to maintain its Nasdaq listing status. The move represents a critical step for the chronic low back pain diagnostic technology provider to meet Nasdaq's continued listing requirement of maintaining a minimum $1.00 bid price.

Following stockholder approval received on December 31, 2024, the company's board of directors set the final split ratio at 1-for-335, meaning every 335 existing shares will be consolidated into one share. The corporate action will dramatically reduce Aclarion's outstanding shares from approximately 169.4 million to 500,000, potentially providing more stability to the stock price.

The reverse split carries significant implications for both retail and institutional investors. While the total value of holdings remains unchanged, investors owning fewer than 335 shares will receive one share in the rounded-up arrangement. The split will also proportionally affect all outstanding warrants, stock options, and restricted stock units, with corresponding adjustments to conversion and exercise prices.

This strategic move highlights ongoing challenges faced by smaller healthcare technology companies in maintaining major exchange listings. For Aclarion, maintaining its Nasdaq presence is crucial for market visibility and access to capital as it continues to develop its Nociscan platform for chronic low back pain diagnosis.